WILLIAMS AND JENSEN, PLLC for PFIZER
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
IP protections related to trade agreements; trade policies impacting pharmaceutical development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | — |
| ERIN BOOK MULLEN | — |
Medicare/Medicaid MMM
Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. CMMI Medicare Part B Demonstration.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| ANDREW JONES | Legislative Counsel, Rep. Hinojosa; Legislative Director and Counsel, Rep Lujan |
| KARINA LYNCH | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
Budget/Appropriations BUD
Labor- H.H.S Appropriations FY 2019; Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act. H.R. 1892, the Bipartisan Budget Act of 2018.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN New | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA New | — |
| CHERYL LYNN JAEGER New | Shrd Employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Majority Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Chris Cox |
Taxation/Internal Revenue Code TAX
Tax issues affecting the pharmaceutical industry including international tax. Revenue proposals on international tax. Implementing of H.R. 1, Tax Cuts and Jobs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages; H.R. 1628, American Health Care Act of 2017. H.R. 1625, Consolidated Appropriations Act of 2018.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| ANDREW JONES New | Legislative Counsel, Rep Hinogosa; Legislative Director and Counsel, Rep Lujan |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.